FDA Assigns PDUFA Date For Shire's FIRAZYR(R) (icatibant) For The Treatment Of Acute Attacks Of Hereditary Angioedema
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, these days announced that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of August 25, 2011 for the review of the New Drug Application (NDA) for FIRAZYR(R) (icatibant) for the treatment of acute attacks (Types I and II) of hereditary angioedema (HAE). This 6 month ...
Read a lot more on Medical News Today
Tuesday, March 29, 2011
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment